BALTIMORE, MD--(Marketwired - Apr 26, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has produced a research update highlighting the recent performance of Nuvilex Inc. (
Small cap oncology stocks are simply on fire of late, leading up to the highly attended ASCO (American Society of Clinical Oncology) annual meeting during the first week of June. It should not be a surprise since many of these stocks, such as Nuvilex, Inc. (
Still, investors have hopped on the Nuvilex bandwagon in droves due to the seasonality effect of ASCO, but also due to the unusually low valuation afforded a stock that appears to be preparing itself for a future Phase III clinical trial for its pancreatic cancer treatment.
Some of the stocks on the move are slated to meet with an FDA advisory panel regarding potential approval of their late stage drugs, which is common this time of year, so that they can present findings or provide news at ASCO. While a number of stocks in the space such as GTX, Inc., and Array Biopharm have enjoyed volume increases, shares of Nuvilex, Inc. (
Nuvilex completed two successful Phase II clinical trials using its live-cell encapsulation platform to treat advanced pancreatic cancer via a targeted approach at the site. The encapsulated cells are able to convert the inactive chemotherapy drug ifosfamide to its active (cancer-killing) form at the site in which they are placed. As a result, the encapsulated cells create a high level of drug in proximity to the pancreatic tumor where the treatment can provide for the greatest anti-tumor effect. Furthermore, by using cell encapsulation in this way, a significant reduction in side-effects was seen since much lower doses (than normally used for cancer treatment) of the chemotherapeutic drug were to be used. Only a single implantation of encapsulated cells was needed and only two "rounds" of drug treatment were employed (usually ifosfamide is given multiple times during a "course" of chemotherapy).
When the results were compared with those of the "standard" single agent (Gemzar) treatment for advanced pancreatic cancer, they demonstrated approximate doubling of both the patients' median survival time and the percentage of 1-year survivors. In addition, Nuvilex's treatment resulted in a lower side effect profile (improved quality of life) as compared to Gemzar.
Considering the difficulty of treating pancreatic cancer, it remains one of the most high profile types of cancer. Coupled with the upside valuation potential and the rise of small cap oncology stock development and their shares ahead of the ASCO meeting, it is likely that Nuvilex remains high on small stock investors' radar screens for the foreseeable future.
To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (